Glenmark Pharmaceuticals, the research-led global integrated pharmaceutical company, announced its first quarter results for the period ending June 30, 2010.
The consolidated net profit for the first quarter was at Rs 155.54 crore, as compared to Rs 53.45 crore for the previous corresponding quarter, an increase of 191 per cent.
The company's consolidated revenue was at Rs 681.86 crore as against Rs 543.68 crore, an increase of 25 per cent. The revenue from the generics business was at Rs 263.59 crore, as against Rs 238.70 crore, a growth of 10 per cent.
The speciality formulation business revenue was at Rs 418.26 crore, as against Rs 304.98 crore for the corresponding quarter of the previous year, registering growth of 37 per cent. The specialty revenue in the first quarter of FY11 includes out-licensing revenue of Rs 89.51 crore.
Content Guide
